Project Oncology®

175 Épisodes

1. Chemotherapy Strategies for Metastatic PDAC

   Publié: 13/01/2025
2. Diagnosis and Management of Metastatic PDAC

   Publié: 13/01/2025
3. Predictive Models for CAR T-Cell Therapy: Personalizing R/R LBCL Care

   Publié: 08/01/2025
4. Sacituzumab Govitecan for mTNBC: A Review of Real-World Efficacy and Safety Data

   Publié: 07/01/2025
5. Mastering CAR-T Cell Therapy in R/R Large B-Cell Lymphoma: Adverse Event Management

   Publié: 07/01/2025
6. Preventing Adverse Events in CAR T-Cell Therapy: The Evolution of Safety Protocols

   Publié: 02/01/2025
7. Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers

   Publié: 31/12/2024
8. Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results

   Publié: 23/12/2024
9. Evaluating Valemetostat and Dato-DXd for NSCLC: An Upcoming Trial

   Publié: 23/12/2024
10. Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases

    Publié: 23/12/2024
11. Dato-DxD for NSCLC: A Review of Final Overall Survival Data from TROPION-Lung01

    Publié: 23/12/2024
12. Understanding Heparin Resistance: Underlying Mechanisms and Alternative Treatment Options

    Publié: 16/12/2024
13. Understanding iMCD Through RNA Sequencing

    Publié: 16/12/2024
14. The Future of ITP Care: Exploring New Treatments

    Publié: 16/12/2024
15. NSCLC Care: Predicting Response to Dato-DXd with a TROP2 Biomarker

    Publié: 13/12/2024
16. Diagnosing Castleman Disease: Key Considerations

    Publié: 10/12/2024
17. Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells

    Publié: 09/12/2024
18. Poster Pearl: Treating ER+/HER2- mBC with Elacestrant and Endocrine Therapy

    Publié: 27/11/2024
19. EMERALD Expert Views: Managing ER+/HER2-, ESR1m mBC Disease Progression Post ET+CDK4/6i

    Publié: 26/11/2024
20. Poster Pearl: Elacestrant + Abemaciclib for ER+/HER2- Metastatic Breast Cancer

    Publié: 29/10/2024